Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...
BioSpace5d
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
FiercePharma8d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
FiercePharma6d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Morningstar8d
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron created Dupixent and markets it jointly in the U.S. with France's Sanofi (FR:SAN) under a 2007 collaboration agreement, while Sanofi markets the product internationally. The drug is ...
U.S. News & World Report8d
Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program
Regeneron, which developed Eylea in collaboration with Bayer AG, seeks to upgrade the eye medication users to a high-dose version as the drug faces threats from biosimilars and rivals, including ...